T-DXd Tolerability in Community-Treated HER2-Low Metastatic Breast Cancer: What Real-World Practice Is Showing
Episode Summary
Trastuzumab Deruxtecan is becoming standard for HER2-low metastatic breast cancer, with safe community use requiring careful monitoring, patient education, and early management of serious lung-related side effects.